For example, secondary mutations in the BCR-ABL kinase domain that disrupt imatinib binding are common among resistant chronic myelogenous leukemia (CML) patients [14]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.